Drugs / Danicamtiv
Danicamtiv
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06027437 | Sep → Nov 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05952089 | Aug 2023 → Mar 2024 | symptomatic heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05806359 | Mar → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05162222 | Dec 2021 → Jul 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03062956 | Jan → Nov 2017 | dilated cardiomyopathy | MyoKardia, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03447990 | Feb 2018 → Oct 2019 | dilated cardiomyopathy, symptomatic heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04572893 | Aug 2020 → Feb 2024 | familial isolated dilated cardiomyopathy | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07210723 | Feb 2026 → Sep 2027 expected | familial dilated cardiomyopathy | Kardigan, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07771465 | Aug 2026 → Nov 2032 expected | familial dilated cardiomyopathy | Kardigan, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-29 | Kardigan, Inc. | Results Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025 kardigan.bio ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-29 | Kardigan, Inc. | Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025 kardigan.bio ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danicamtiv | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07771465 ↗ |
| Known as | MYK-491 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03447990 ↗ |
| Known as | SAR-440181 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594304 ↗ |
| Action | Activate | “Danicamtiv is a novel investigational small molecule that selectively enhances cardiac myosin function.” PMID 41217321 ↗ Sep 2025 |
| Modality | Small molecule | “Danicamtiv is a novel investigational small molecule that selectively enhances cardiac myosin function.” PMID 41217321 ↗ Sep 2025 |
| Route | Oral | “single-dose, oral suspension” NCT03062956 ↗ |